FDA Approves New Flu Shot Using COVID-Era Tech—Here’s Who Can Get It
Summary
The FDA has approved mFLUSIVA, a new flu vaccine made by Moderna using the same mRNA technology as their COVID-19 vaccine. It is authorized for adults aged 50 and older, with full approval for 50-64-year-olds and conditional approval for those 65 and older pending more studies.Key Facts
- mFLUSIVA is the first flu shot in the U.S. made with mRNA technology.
- The vaccine is approved for people aged 50 and older.
- Adults 50 to 64 received full approval based on strong effectiveness data.
- Adults 65 and older have conditional approval, requiring further studies to confirm results.
- In a large trial with over 40,000 participants, mFLUSIVA prevented flu illness better than a standard flu vaccine by about 26.6%.
- The vaccine teaches the body to make specific flu proteins without using live virus or egg-based ingredients.
- Common side effects include soreness at the injection site, headache, fatigue, chills, and muscle aches, usually mild and short-lived.
- People allergic to this vaccine should not receive it.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
